Sallman, D., Malki, M., Asch, A., Wang, E., Jurcic, J., Bradley, T., . . . Daver, N. (2022). MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results. Elsevier.
Chicago Style (17th ed.) CitationSallman, D., et al. MDS-445 Magrolimab in Combination with Azacitidine for Patients with Untreated Higher-risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results. Elsevier, 2022.
MLA (9th ed.) CitationSallman, D., et al. MDS-445 Magrolimab in Combination with Azacitidine for Patients with Untreated Higher-risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results. Elsevier, 2022.
Warning: These citations may not always be 100% accurate.